|Articles|March 22, 2021
Nephron Pharmaceuticals Integrates STERIS VHP Biodecontamination System
Author(s)STERIS Life Sciences
This case study examines the benefits and challenges Nephron Pharmaceuticals Corporation faced integrating a STERIS VHP® Biodecontamination system into their high-volume compounding facility.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Novartis Calls for Global Governments to Address Global Trade Policy
2
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
3
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
4
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
5